v3.26.1
Segment Reporting - Schedule of Segment Information (Details) - USD ($)
 3 Months Ended
Apr. 30, 2026
Apr. 30, 2025
Net Sales    
Net sales total $ 433,399 $ 667,432
Operating Expense    
Selling, general and administrative 1,203,891 982,052
Goodwill and intangibles impairment
Research and development - 4P Therapeutics 247,261 683,426
Depreciation and Amortization    
Depreciation and amortization total 34,177 57,480
Reportable Subsegments [Member]    
Net Sales    
Net sales total 433,399 667,432
Gross Profit    
Gross profit total 196,801 251,981
Operating Expense    
Total 1,451,234 1,665,478
Depreciation and Amortization    
Depreciation and amortization total 34,177 57,480
Pocono Pharmaceuticals [Member] | Reportable Subsegments [Member]    
Net Sales    
Net sales total 433,399 667,432
Gross Profit    
Gross profit total 196,801 251,981
Depreciation and Amortization    
Depreciation and amortization total 24,910 42,813
4P Therapeutics [Member] | Reportable Subsegments [Member]    
Net Sales    
Net sales total
Gross Profit    
Gross profit total
Depreciation and Amortization    
Depreciation and amortization total 9,267 9,267
Selling, general and administrative - Pocono Pharmaceuticals [Member] | Reportable Subsegments [Member]    
Operating Expense    
Selling, general and administrative 156,788 151,528
Selling, general and administrative - 4P Therapeutics [Member] | Reportable Subsegments [Member]    
Operating Expense    
Selling, general and administrative 6,483 19,999
Selling, general and administrative - Corporate [Member] | Reportable Subsegments [Member]    
Operating Expense    
Selling, general and administrative 1,049,734 810,525
Corporate [Member] | Reportable Subsegments [Member]    
Depreciation and Amortization    
Depreciation and amortization total
Goodwill and intangibles impairment [Member] | Reportable Subsegments [Member]    
Operating Expense    
Goodwill and intangibles impairment
Research and development - 4P Therapeutics [Member] | Reportable Subsegments [Member]    
Operating Expense    
Research and development - 4P Therapeutics $ 238,229 $ 683,426